President Donald Trump’s recent attacks on the pharmaceutical industry have led to a downturn in drug company shares, prompting a mixed reaction among investors. While some lawmakers are capitalizing on the market volatility by investing in pharmaceutical stocks, others are concerned about the broader implications for healthcare costs and innovation.
In recent weeks, Trump has criticized the industry for high drug prices and promised regulatory changes that could impact the sector. This has led to uncertainty in the market, with some investors looking to profit from the volatility while others are cautious about the long-term effects on the industry.
Lawmakers, including both Republicans and Democrats, have expressed mixed views on the issue. While some see the potential for investment, others are pushing for reforms that could provide relief to patients and reduce the financial burden on the healthcare system.